Mechanisms, drug development, biomarkers, and precision psychiatry — the science and pipeline behind psychiatric medicine.
GLP-1 medications used to treat diabetes and obesity were associated with a reduced need for hospital care and sickness absence due to psychiatric reasons, a new study shows.…
What if the next leap in psychiatric treatment doesn’t come from tweaking dopamine or serotonin, but from reengineering the immune system, harnessing neuroplasticity, or refining orexin antagonism? In…
By mid-2025, the psychopharmacology landscape feels paradoxical: on one hand, deeply familiar challenges — slow response, heterogeneity, side effects — still dominate clinical reality. On the other, a…
Objective Many psychotropic drugs are highly associated with related weight gain. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are established anti-obesity and glucose-lowering agents. Preliminary evidence also indicates they are…
Two drugs have emerged as the optimal medications for treating insomnia based on the “best-available evidence,” but there are caveats. In a comprehensive comparative-effectiveness analysis, lemborexant and eszopiclone showed the best efficacy,…
A novel, noninvasive, over-the-counter electromagnetic neuromodulation device (ActiPatch, BioElectronics Corp.) appears to deliver long-lasting relief in chronic pain patients. Results of a long-term prospective study that included 240…
